Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Antisense Therapeutics Limited (AU:ANP)
ASX:ANP
RESEARCH TOOLSreports
Holding AU:ANP?
Track your performance easily
ANP Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.05 - AU$0.11
Previous CloseAU$0.06
Volume324.28K
Average Volume (3M)543.80K
Market Cap
AU$54.99M
Enterprise ValueAU$35.99M
Total Cash (Recent Filing)AU$19.23M
Total Debt (Recent Filing)AU$227.40K
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Feb 28, 2024EPS Estimate
-AU$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding901,544,971
10 Day Avg. Volume1,179,938
30 Day Avg. Volume543,802
Standard Deviation0.31
R-Squared0.00021
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.15Price Target Upside155.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Options Prices
Currently, No data available
---
Ownership Overview
2.34% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
97.66% Public Companies and
Individual Investors
ANP FAQ
What was Antisense Therapeutics Limited’s price range in the past 12 months?
Antisense Therapeutics Limited lowest share price was AU$0.05 and its highest was AU$0.11 in the past 12 months.
What is Antisense Therapeutics Limited’s market cap?
Currently, no data Available
When is Antisense Therapeutics Limited’s upcoming earnings report date?
Antisense Therapeutics Limited’s upcoming earnings report date is Feb 28, 2024 which is 298 days ago.
How were Antisense Therapeutics Limited’s earnings last quarter?
Antisense Therapeutics Limited released its earnings results on Aug 25, 2023. The company reported -AU$0.009 earnings per share for the quarter, beating the consensus estimate of -AU$0.015 by AU$0.006.
Is Antisense Therapeutics Limited overvalued?
According to Wall Street analysts Antisense Therapeutics Limited’s price is currently Undervalued.
Does Antisense Therapeutics Limited pay dividends?
Antisense Therapeutics Limited does not currently pay dividends.
What is Antisense Therapeutics Limited’s EPS estimate?
Antisense Therapeutics Limited’s EPS estimate is -AU$0.01.
How many shares outstanding does Antisense Therapeutics Limited have?
Antisense Therapeutics Limited has 901,545,000 shares outstanding.
What happened to Antisense Therapeutics Limited’s price movement after its last earnings report?
Antisense Therapeutics Limited reported an EPS of -AU$0.009 in its last earnings report, beating expectations of -AU$0.015. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Antisense Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:ANP
---
Antisense Therapeutics Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.15 (155.18% Upside)
AU$0.15 (155.18% Upside)
Blogger Sentiment
Bullish
AU:ANP Sentiment 96%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $4.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.84%
12-Months-Change
Fundamentals
Return on Equity
-72.31%
Trailing 12-Months
Asset Growth
-44.59%
Trailing 12-Months
Company Description
Antisense Therapeutics Limited
Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The ATL1103 segment refers to atesidorsen is an antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin. The company was founded in November 13, 2000 and is headquartered in Toorak, Australia.
---
ANP Stock 12 Month Forecast
Average Price Target
AU$0.15
▲(155.18% Upside)
Technical Analysis
Antisense Therapeutics Limited
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Intellia Therapeutics
―
Best Analysts Covering ANP
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-36.37%
reiterated a buy rating a year ago
Copying Melissa Benson's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -36.37% per trade.
---